期刊
CLINICAL INFECTIOUS DISEASES
卷 57, 期 -, 页码 S105-S110出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cit301
关键词
mixed infection; substance abuse; hepatitis C virus; clearance; sequence analysis
资金
- International Network on Hepatitis in Substance Users (INHSU)
- Kirby Institute (University of New South Wales)
- Abbvie
- Gilead Sciences
- Janssen-Cilag
- Merck
Most new cases of hepatitis C virus (HCV) infections in the developed world are associated with injection drug use. However, treatment for people who inject drugs (PWID) is controversial, as successful treatment risks being followed by new infection. Reinfection after sustained virologic response has been reported, but is the risk so great that treatment should be withheld from this large HCV population? Preliminary evidence suggests that the reinfection incidence is low, but studies to date have been limited by small sample size and few cases of reinfection. In this review, we assess data from studies among PWID of HCV reinfection following treatment to give a reasonable estimate on how frequently reinfection appears and try to characterize those most at risk, The observation that spontaneous clearance of HCV reinfection following treatment occurs is suggestive of a partial protective immunity against persistent infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据